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Dysregulation of proteolytic processing of the amyloid precursor protein (APP) contrib-
utes to the pathogenesis of Alzheimer’s Disease, and the Group VIA phospholipase A2
(iPLA2) is the dominant PLA2 enzyme in the central nervous system and is subject to
regulatory proteolytic processing. We have identified novel N-terminal variants of iPLA2
and previously unrecognized proteolysis sites in APP constructs with a C-terminal 6-myc
tag by automated identification of signature peptides in LC/MS/MS analyses of proteo-
lytic digests. We have developed a Signature-Discovery (SD) program to characterize
protein isoforms by identifying signature peptides that arise from proteolytic processing in
vivo. This program analyzes MS/MS data from LC analyses of proteolytic digests of
protein mixtures that can include incompletely resolved components in biological samples.
This reduces requirements for purification and thereby minimizes artifactual modifications
during sample processing. A new algorithm to generate the theoretical signature peptide
set and to calculate similarity scores between predicted and observed mass spectra has
been tested and optimized with model proteins. The program has been applied to the
identification of variants of proteins of biological interest, including APP cleavage
products and iPLA2, and such applications demonstrate the utility of this
approach. (J Am Soc Mass Spectrom 2004, 15, 1780 –1793) © 2004 American Society for
Mass SpectrometryDeposition of amyloid in central nervous sys-tem tissue is a key event in the pathogenesisof Alzheimer’s Disease, and peptides derived
from cleavage of the amyloid precursor protein (APP)
differ in their amyloidogenicity [1, 2]. Considerable
effort is thus directed at characterizing the proteolytic
processing of APP by identifying the responsible
proteases, their cleavage sites, and the resultant prod-
uct peptides. The Group VIA Phospholipase A2
(iPLA2) is the dominant cytosolic PLA2 activity in
the central nervous system, and a number of isoforms
of this enzyme with different properties are ex-
pressed in various cells [3–10]. Some iPLA2 variants
arise from alternative splicing of transcripts, and
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doi:10.1016/j.jasms.2004.08.012others arise from proteolytic processing at both the
C-terminus and the N-terminus of the parent iPLA2
sequence. Characterization of cleavage sites of
iPLA2 is required to understand its processing and
the structures and functions of its variant isoforms.
Identification of variants of proteins that arise from
the same gene, such as that for APP or iPLA2, is a
problem in proteomics [11], which is the study of gene
products that are far more diverse than the set of genes
from which they arise. Among mechanisms for gener-
ating such diversity are alternative splicing of tran-
scripts and post-translational modification (PTM) [12–
14]. PTM can include covalent modification of amino
acid residues, e.g., phosphorylation of side-chain hy-
droxyl groups, or proteolytic processing by exopeti-
dases or endopeptidases. Mass spectrometry has now
become a principal tool for identification of proteins
and their variant forms [11]. Fairly pure proteins with
MW below 10 kDa can often be successfully analyzed
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facilitate identification of protein variants or isoforms
with high throughput [15], but the MW of many pro-
teins is greater than 10 kDa. Proteins in biologic samples
are also often incompletely resolved components of
complex mixtures, and accurate mass measurements
alone may be insufficient to achieve unambiguous
identifications of protein variants or isoforms.
A frequently employed approach to protein identifi-
cation is to digest the sample with proteolytic enzymes
of known sequence specificity [11]. For a purified
sample containing a small number of proteins, peptide
mapping is often sufficient to identify proteins by
comparing the observed proteolytic peptide masses
with the predicted peptide masses calculated from
protein or gene databases that specify protein se-
quences directly or by deduction [16–22]. For more
complex protein mixtures, tandem mass spectrometry
(MS/MS) is required to obtain amino acid sequence
information, which is deduced from fragmentation pat-
terns of individual proteolytic peptides [11]. Computer
assistance is required to process the large amount of
data generated by LC/MS/MS analyses of such peptide
mixtures. The MS/MS data are submitted to database
searching [23–25] or to de novo sequencing programs
[26–28]. Some programmed algorithms have been de-
veloped to identify protein PTMs [29, 30] from MS/MS
data.
When a protein in a biological sample represents the
product of in vivo proteolytic processing of a parent
protein, digestion of the product protein in vitro with
Figure 1. Illustration of a signature peptide fro
processing.exogenous proteases, e.g., trypsin, to yield a set ofpeptides for protein identification often generates a
signature peptide that can be used to identify the site of
in vivo proteolytic processing. A signature peptide is
one that arises from digestion of a protein derived from
the same gene as a parent protein, but which lacks a
region of amino acid sequence contained by the parent
protein. Such peptides would not be produced from
digestion of the parent protein by the given protease
but appear because of missing sequence in the protein
variant that has been removed by in vivo processing.
An example of identifying a signature peptide that
reflects an in vivo proteolytic processing event ap-
peared in one of the earliest reports of what has become
a standard approach in proteomics, which is to analyze
proteins from a biological source by 2-D gel electro-
phoresis, to subject isolated protein spots to tryptic
proteolysis, and to analyze the peptides in the digest by
peptide mass mapping with MALDI/TOF/MS and
then, when necessary, by LC/MS/MS to obtain peptide
sequence information [31]. When analyzing a yeast
proteome in this manner, Shevchenko et al. encoun-
tered a protein of apparent molecular mass of 38.8 kDa
and isoelectric point of 6.45 that yielded a peptide mass
map that had 30 peaks that closely matched expected
tryptic peptides for yeast protein ILV5, but native ILV5
has a calculated molecular mass of 44.4 kDa and an
isoelectric point of 9.46 [31].
Because the C-terminal tryptic peptide of ILV5 ex-
pected from the native sequence was observed in the
MALDI/TOF mass spectrum, it was suspected the 38.8
kDa protein arose from 44.4 kDa ILV5 by N-terminal
iPLA2 variant that reflects in vivo proteolyticm anproteolytic processing. The N-terminal sequence of
e Sig
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from the 44.4 kDa sequence would yield a protein of
38.8 kDa with an isoelectric point of 6.45. Because the
peptide bond between residues 47 and 48 does not
represent a normal tryptic cleavage site, digestion of the
38.8 kDa protein with trypsin would be expected to
yield a new tryptic peptide beginning at residue 48 with
an [M  H] m/z value of 1853.909. Such a peak was
observed in the MALDI/TOF mass spectrum, confirm-
ing that the 38.8 kDa protein arose from removal of
residues 1–47 of the native 44.4 kDa ILV5 sequence. The
peptide of m/z 1853.909 is thus a “signature peptide”
that reflects nontryptic proteolytic processing that has
presumably occurred in vivo [31].
Sequence information can also be useful in identify-
ing such signature peptides. Figure 1 illustrates a case
that will be described further in the Results and Discus-
sion section. For the iPLA2 enzyme, the cloned cDNA
encodes a protein with the sequence 1MGFFGR. Diges-
tion of the native sequence with trypsin would be
expected to yield the peptides 1M-R6, 7L-R23, 24A-K25,
26EVSLA, but iPLA2 is subject to N-terminal proteo-
lytic processing. Among the variants produced is one
from which residues 1M-L11 have been removed to yield
a truncated protein that begins with residue 12S. Tryptic
digestion of this truncated variant yields the peptide
12S-R23, which would not be expected to arise from
Figure 2. Flow chart of thtryptic digestion of the full-length protein. The se-quence of the peptide 12S-R23, however, matches that
encoded by iPLA2 cDNA. In this case, the peptide
12S-R23 is a signature peptide that reflects nontryptic
proteolytic processing to remove the N-terminal 11
amino acid residues from the full-length iPLA2
sequence [3].
To identify such peptides, derivatization methods
have been used to isolate N-terminal signature pep-
tides from digest mixtures [32]. Although derivatiza-
tion is sometimes incomplete and digestion with a
single protease might yield low sequence coverage,
this approach has achieved identification of 264 pro-
teins from human thrombocytes [32]. Eleven of them
were different isoforms of the same gene product that
were produced by N-terminal processing. Because de
novo sequencing has limited accuracy and because
peptide mixtures that result from digestion of incom-
pletely purified biological samples are complex, it is
often difficult to identify signature peptides by direct
inspection of the MS/MS data, and, computer assis-
tance with data interpretation is required.
Here we describe an approach to analyze LC/
MS/MS data from peptide mixtures that can identify
signature peptides and protein isoforms that arise
from endogenous proteolytic processing. A new
method to generate the signature peptide candidates
has been developed for our approach and greatly
nature-Discovery Program.reduces the number of members of the signature
ein, t:
ation
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tional time. In addition, we have developed an opti-
mized similarity score calculation that considers both
fragmentation and intensity information, making the
signature peptide identification more reliable. Our
Signature-Discovery (SD) program implements this
approach to analyze LC/MS/MS data of proteolytic
digests of protein mixtures and identify signature
peptides automatically. The SD program perfor-
mance has been tested with model proteins and
biological samples from cellular expression systems.
Such analyses have resulted in identification of pre-
viously unrecognized cleavage sites for processing of
iPLA2 and of an APP construct.
Experimental Procedures
Materials
All chemicals were purchased from Sigma Chemical (St.
Louis, MO) and all solvents from Fisher Chemical (St.
Louis, MO) unless otherwise stated. PepMap HPLC
columns and pre-columns were obtained from LC-
Packings (San Francisco, CA).
Cloning, Expression, and Purification of Native
and His-Tagged iPLA2 Proteins in Sf9 cells
S. frugiperda (Sf9) cells were cultured as described
Table 1. Dual enzyme peptides identified by the Signature-Disc
Sequence Expected Mass
Start
AA
End
AA
(E)WQQVLNVWGK(a) 1257.6750 7 16
(E)REDLIAYLK(c) 1120.6359 91 99
(E)NFVAFVDK(b) 939.4942 573 580
(R)LFTGHPETLE(a) 1143.5686 32 41
(K)YKVPQLE(s) 875.4827 119 125
(K)EPMIGVNQE(s) 1016.4735 148 156
(D)YGILQINSR(l) 1063.5897 71 79
(D)LLIGSSQDDGLINR(t) 1500.8026 2507 2520
(K)VEADIAGHGQE(a) 1125.5183 17 27
(E)YGFQNALIVR(b) 1180.6480 424 433
(R)HPYFYAPE(b) 1023.4583 169 176
(E)FISDAIIHVLHSK(a) 1479.8326 106 118
(K)HQGLPQEVLNE(s) 1263.6335 23 33
(E)DYLSLILNR(b) 1106.6207 474 482
(R)KVPQVSTPTLVE(b) 1297.7373 437 448
(E)LLYYANK(b) 884.4884 177 183
(D)SGIFQPMLQGR(t) 1233.6415 419 429
(R)FFVAPFPE(s) 953.4785 38 45
(K)EGIHAQQKEPMIGVNQE(s) 1907.9297 140 156
(E)ADIAGHGQEVLIR(a) 1378.7443 19 31
(E)LSVLLPNRQGLKK(t) 1465.9215 2701 2713
(E)DLIAVLK(c) 835.4925 93 99
(E)DQSCPSERRR(t) 1233.5753 361 370
(K)ECCHGDLLECAD(b) 1307.4707 267 278
(E)YAVSVLLR(b) 920.5582 364 371
a: Apo-myoglobin, c: Cyto-chrome-C, b: Bove serum albumin, s: -Cas
aItem 1 is the calculated value of first item in eq 1; Item 2 is the calculelsewhere [33–36]. For expression of iPLA2 protein, a250-ml flask was prepared with a suspension of 50 ml of
106 cells/ml and incubated at 27°C for 24 h before
infection with baculovirus. For protein expression,
cDNA containing the entire coding sequence of native
iPLA2 [37] or his-tagged iPLA2 with the tag at either
the C-terminus or at the N-terminus [38], or was cloned
into the EcoRI-SalI site of the pFASTBACtm 1 baculovi-
rus expression vector. The sequence of the insert was
verified, and the plasmid was then transformed into
DH10Bac cells according to instructions in the Bac-To-
Bac system manual. Recombinant bacmid DNA was
isolated from small-scale cultures using an alkaline lysis
protocol modified for high-molecular-weight plasmid
purification. PCR analysis was performed with purified
bacmid DNA and pUC/M13 amplification primers to
determine the size of inserts.
Typically, Sf9 cell suspensions (50 ml of 106 cells/ml)
in supplemented Grace’s medium were infected with 1
ml of baculovirus. Sf9 cells were collected by centrifu-
gation (500  g, 10 min, 4°C), washed with PBS buffer,
and re-suspended in lysis buffer (25 mM NaH2PO4, 2
mM -mercaptoethanol, 5 g/ml leupeptin, pH 7.8).
The cells were disrupted by sonication, and the cytosol
was prepared by subsequent centrifugation (18,000 g,
15 min). His-tagged proteins were purified with a
TALON metal affinity column and detected by Coo-
massie stain protein gel and immunoblotting. The Sf9
cell homogenate containing his-tagged iPLA2 proteins
program from digests of a mixture of model proteins
lculated
mass
Observed
mass
Charge
state Item1a Item2a
Similarity
score
257.6654 629.3327 2 0.50 0.70 0.60
120.6324 560.6162 2 0.43 0.75 0.59
939.4906 470.2483 2 0.40 0.70 0.55
143.5632 572.2816 2 0.53 0.55 0.54
876.4648 438.7324 2 0.81 0.25 0.53
016.4514 508.7257 2 0.61 0.40 0.51
063.5848 532.2924 2 0.46 0.55 0.51
500.799 750.8995 2 0.39 0.60 0.50
125.504 563.252 2 0.42 0.55 0.49
180.6474 590.8237 2 0.37 0.60 0.48
023.4616 512.2308 2 0.35 0.55 0.45
479.8269 493.9423 3 0.31 0.50 0.40
263.5676 632.2838 2 0.35 0.45 0.40
106.6392 553.8196 2 0.31 0.45 0.38
297.7684 649.3842 2 0.33 0.40 0.37
884.4962 442.7481 2 0.33 0.40 0.36
233.647 617.3235 2 0.33 0.25 0.29
953.4628 477.2314 2 0.22 0.30 0.26
907.9008 636.6336 3 0.19 0.30 0.25
378.8386 689.9193 2 0.21 0.20 0.21
465.7136 733.3568 2 0.21 0.21 0.21
835.4796 418.2398 2 0.13 0.30 0.21
233.647 617.3235 2 0.21 0.10 0.15
307.7456 654.3728 2 0.22 0.00 0.11
920.5558 460.7779 2 0.04 0.10 0.07
Thyroglobulin, l: Lysozyme.
value of first item in eq 1.overy
Ca
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1was mixed with TALON metal affinity resin (Clontech,
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1 h. The mixture was washed with 10 bed volumes of
wash buffer (50 mM Na2HPO4, 500 mM NaCl, 10 mM
imidazole, pH 7.8) twice and transferred onto a gravity-
flow column. The his-tagged iPLA2 was eluted with
elution buffer (50 mM Na2HPO4, 300 mM NaCl, and 200
mM imidazole, pH 7.8) and collected in 0.5 ml fractions.
Native iPLA2 was purified as described elsewhere [9,
34, 35]. Coomassie stained protein gels and immuno-
blotting analyses were used to visualize iPLA2 and
his-tagged iPLA2.
Generation and Immunoprecipitation
of Proteolytic Products from myc-Tagged APP
Constructs
The cDNA constructs for presenilins and APP-6myc
were generated as described previously [39]. Human
embryonic kidney 292 (HEK) cells were obtained from
the ATCC (Rockville, MD) and maintained in DMEM
(GibcoBRL, Grand Island, NY) containing 10% fetal
bovine serum (GibcoBRL), 2 mM L-glutamine, 100
g/ml penicillin under a 5% CO2/95% air atmosphere.
Figure 3. The MS/MS spectrum of potential du
(E)DLIAYLK with a similarity score of 0.21; (b)
a similarity score of 0.15.Pooled stable cell lines expressing presenilins weregenerated by transfecting HEK parental cells with the
appropriate DNA constructs and selecting with G418,
as previously described [39]. Cells were transfected
with various constructs using FuGENE 6 transfection
reagent (Roche Molecular Biochemicals, Indianapolis,
IN). Forty-eight h after transfection, cells were lysed in
co-IP lysis buffer (50 mM Tris, pH 7.6, 150 mM NaCl, 2
mM EDTA, 1% NP40 and 0.5% Triton X-100). About
10% of the lysates were used for immunoblotting anal-
ysis. The remaining lysates were cleared with Protein A
agarose beads (Santa Cruz Biotechnology, Santa Cruz,
CA) and incubated with anti-myc monoclonal antibody
9E10 (Sigma) and 40 l Protein A at 4°C overnight with
constant rotation. The immunoprecipitates were
washed twice with wash buffer 1 (50 mM Tris, pH 7.6,
500 mM NaCl, and 2 mM EDTA), twice with wash
buffer 2 (50 mM Tris, pH 7.6, 150 mM NaCl, 2 mM
EDTA), as previously described [39], and then sus-
pended in buffer for proteolysis.
Digestion with Proteolytic Enzymes
Samples were concentrated to dryness under nitrogen
zyme peptides: (a) MS/MS spectrum of peptide
MS spectrum of peptide (E)DQSCPSERRR withal en
MS/and rehydrated in a solution of 50 mM NH4HCO3.
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Madison, WI) or sequencing grade modified Glutamic
C endopeptidase (Princeton Separations, Adelphia, NJ)
was added at a ratio of 1/50 (wt/wt). After 12 h
incubation at 37°C, the digest was adjusted to pH 2 and
analyzed by LC/MS/MS.
MALDI/TOF Mass Spectrometry
MALDI/TOF mass spectra were acquired with a
Voyager DE STR instrument (Applied Biosystems,
Foster City, CA). The matrix solution was saturated
3,5-dimethoxy-4-hydroxycinnamic acid in 50% aceto-
nitrile with 0.1% formic acid for peptide analyses and
sinapinic acid for protein analyses. The mass spec-
trometer was calibrated with insulin, cytochrome c,
myoglobin, and BSA in linear mode or with trypsin
autolysis peptides in reflectron mode.
LC/MS/MS
Samples (0.2 l) were injected into a Micromass CapLC
liquid chromatography system (Micromass, Manches-
ter, UK) and pre-concentrated on a 300 m  5 mm
PepMap C18 precolumn. The sample on the precolumn
was washed for 3 min with 0.1% formic acid at a flow
rate of 30 L/min, eluted onto an analytical C18 col-
umn (150 mm  17m), and then analyzed with a
solvent gradient from solution A (3% acetonitrile) to
Solution B (95% acetonitrile) containing 0.1% formic
acid over 50 min at a flow rate of 200 nL/min. The flow
rate from pumps A and B was 5 L/min and was
reduced to 200 nL/min by stream splitting.
Figure 4. Immunoaffinity (a) and Coomassie b
cobalt affinity columns. N: N-terminal His-tag
homogenate, 2: the second eluant.
Table 2. Signature peptides identified by the Signature-Discove
Sequence
Expected
mass StartAA EndA
SSVTNLFSNPFR 1368.691 12- 23
SVTNLFSNPFR 1281.659 13- 23
NTLSSVTNLFSNPFR 1696.866 9- 23The LC eluant was introduced into the nanoflow
source interfaced with a Micromass Q-TOF Micro
mass spectrometer (Micromass, Manchester, UK).
The source temperature was 80°C, and the cone gas
flow was 50 L/hr. A voltage of 3.2 kV was applied to
the nanoflow probe tip, and data were acquired in
positive ion mode. The survey scans were integrated
over one second, and the MS/MS scans were inte-
grated over three seconds. Switching from survey
scan to MS/MS scan mode was performed in a
data-dependent manner. The maximum MS/MS scan
to survey scan ratio was three. The collision energy
was 28 eV. Data were processed using Masslynx
version 3.5 software. Multi-point calibration was per-
formed using selected fragment ions that resulted
from the collision-induced decomposition of Glu-
fibrino-peptide B. MS/MS spectra were processed by
Masslynx software to produce a peak list file.
Signature-Discovery Algorithm
Figure 2 is the flow chart of the program to identify
signature peptides derived from protein isoforms or
variants. The theoretical set of peptides and their amino
acid sequences are generated from the known sequence
of the target protein and the sequence specificity of the
protease used for digestion. A set of potential signature
peptides and their sequences is then generated from the
set of peptides produced from digestion of the target
protein. The algorithm generates the signature peptide
set by removing one amino acid sequentially from the
N- or C-terminus of each expected peptide in the digest
of the target protein. This potential signature peptide
tain (b) of SDS PAGE analysis of eluants from
2; C: C-terminal His-tag iPLA2. Subscript H:
ogram from a trypsin digest of iPLA2
Calculated
mass
Observed
mass
Charge
state
Similarity
score
1368.629 684.8147 2 0.58
1281.622 641.3112 2 0.54lue s
iPLAry pr
A1696.814 848.9069 2 0.50
1786 SONG ET AL. J Am Soc Mass Spectrom 2004, 15, 1780–1793set will thus include peptides that arise from either the
N- or C-terminus or from somewhere in the middle of
the sequence. The algorithm would not detect products
of unexpected splice variant mRNA species that contain
some region of internal sequence not encoded by the
cDNA species to which the peptide data is compared. If
specific splice variants are known to exist, the peptide
data set can be compared with the deduced amino acid
sequence of more than one splice variant cDNA species.
Generating the potential signature peptide set from
proteolytic peptides rather than from the entire amino
acid sequence of the target protein dramatically reduces
the size of the theoretical signature peptide set but does
not sacrifice sequence coverage. If the target protein has
700 amino acid residues, for example, over 260,000
different potential signature peptides will be generated
from the entire amino acid sequence using commercial
software [23], but our algorithm generates only 820
candidate peptides. This reduces the complexity of the
calculation by over 300-fold.
To include all potential signature peptides in the
theoretical set, we allow up to five missed cleavages,
and we use multiple proteases with different se-
quence specificity. The theoretical MS/MS spectrum
of each candidate signature peptide is then generated
from peptide CAD fragmentation rules. The solution
containing the target protein and its variants is then
Figure 5. Tandem mass spectra of different sig
with a C-terminal His-tag: (a) the tandem mass s
isoform (7L-R23); (b), (c), and (d), the tandem ma
13S-R23) that represent truncated isoforms.digested with the protease selected for generation ofthe theoretical data set, and the resultant digest is
analyzed by LC/MS/MS. Acquired and theoretical
MS/MS spectra are then compared with each other in
order to select signature peptide candidates in a
two-step procedure. First, the molecular weights of
peptides from the theoretical and actual data sets are
compared. If peptides with identical molecular
weights (within an error limit) are found in the two
data sets, then the similarity of their MS/MS spectra
is evaluated by an algorithm that generates a similar-
ity score (eq 1 in the next section). Peptides with a
high similarity score are identified as candidate sig-
nature peptides. Finally, all the selected peptides are
sorted by the similarity score, and a higher score
reflects a greater likelihood of correct identification.
Results and Discussion
Score Calculation
For a given molecular weight, there can be more than
one candidate matching peptide, and each will have an
amino acid sequence that differs from that of the others
[40]. The accuracy of the similarity score is thus impor-
tant in correctly identifying signature peptides. Gener-
ally, individual fragment ions of similar m/z value from
the acquired and theoretical spectra are compared pair
e peptides identified in tryptic digest of iPLA2
um of the expected peptide from the full length
ectra of signature peptides (9N-R23, 12S-R23, andnatur
pectr
ss spby pair. If the m/z difference between the two ions is less
inal
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included in the similarity score calculation [41]. Peptide
fragmentation information (first item in eq 1 below) is
the most important component of the similarity score
calculation. If the spectrum is noisy, fragmentation
information alone is insufficient to identify the correct
sequence, and intensity information (second item in eq
1 below) must also be considered in the similarity score
calculation. In our similarity score calculation algo-
rithm, the intensity information is included by counting
the matched fragment ions in the 20 most intense
spectral lines in the acquired spectrum.
Score NmatchNtheoretical  kNmatch2020  ⁄ 2 (1)
Nmatch is the number of matched spectral lines in the
theoretical and actual MS/MS data. Ntheoretical is the
number of spectral lines in the theoretical MS/MS
spectrum. Nmatch20 is the number of matched spectral
lines in the 20 most intense spectral lines in the acquired
MS/MS spectrum. The parameter k is a correction
Figure 6. MALDI/TOF mass spectrum of t
His-tagged iPLA2 bands in Figure 3, (a) C-termfactor, and k  1  Ntheoretical  Ntheoreticalmin ⁄Ntheoreticalmax Ntheoretical
min . It is used to correct for discrimination against
smaller peptides when counting the matched fragment
ions among the 20 most intense spectral lines.
To evaluate the similarity score calculation algorithm
and to select an appropriate similarity score threshold,
the standard proteins -casein, cytochrome c, apomyo-
globin, BSA, lysozyme and thyroglobulin were incu-
bated with a mixture of two proteases (trypsin and
Glu-C) at 37°C for 12 h. The digests were then analyzed
by LC/MS/MS, and Masslynx 3.5 software was used to
produce a peak list file for the MS/MS spectra. With a
mixture of two proteases, the digest should contain
three different kinds of peptides: (1) peptides generated
by trypsin cleavage; (2) peptides generated by Glu-C
cleavage; and (3) peptides in which one terminus is
generated by trypsin cleavage and the other by Glu-C
cleavage, which are designated as dual-enzyme cleav-
age peptides.
Because such dual-enzyme peptides contain N- and
C-termini produced by different proteases, they repre-
sent surrogate signature peptides that can be used to
optimize the experimental similarity score threshold.
eptide mixture from in-gel digestion of the
His-tag iPLA2; (b) N-terminal His-tag iPLA2.he pTable 1 lists the entire set of potential dual-enzyme
ami
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larity scores. Comparisons by direct inspection of the
corresponding acquired MS/MS spectrum to the amino
acid sequence deduced by our SD program resulted in
selection of 0.2 as an appropriate similarity score
threshold value. That value is used in subsequent
calculations. Comparisons that yield a similarity score
that is less than 0.2 are not considered acceptable
matches, but, if desired, such spectra could be further
evaluated by direct inspection.
If the quality of MS/MS spectrum is poor (e.g., few
fragment ions are recorded or the spectrum is noisy),
intensity information (the second item in eq 1 above)
plays a critical role in correct identification of dual-
enzyme peptides. Figure 3a is the MS/MS spectrum of
the identified dual-enzyme peptide (E)DLIAYLK from
cytochrome c. Because too few fragment ions are re-
corded in the MS/MS spectrum, the calculated value of
the first item in eq 1 (the contribution of its fragmenta-
tion information) is only 0.13, but the predicted frag-
ment ions of this peptide (especially the y-ions) match
most of the high intensity peaks in the observed spec-
trum. This causes the second item (eq 1, intensity
information) to have a calculated value of 0.3. This
peptide is thus identified as a dual-enzyme peptide
Figure 7. MALDI/TOF mass spectrum of the
myc-tagged APP cleavage products. The arrow
variant of the C-terminal fragment starting with
Table 3. Signature peptide identified from the tryptic digest of
Sequence Expected mass StartAA EndAA Calc
FEQMHR 847.3889 46- 51
ESLGDLTMEQK 1250.593 121- 131 1250.with a similarity score of 0.21. Although the MS/MS
spectrum (Figure 3b) of peptide (E)DQSCPSERRR from
thyroglobulin has more fragment ions, most high inten-
sity peaks do not match predicted fragment ions, and
the similarity score in this case is lower when both the
fragment and intensity data are considered together.
Identification of Four Different Isoforms of Group
VIA Phospholipase A2 expressed from its cDNA
The Group VIA Phospholipase A2 (iPLA2) enzyme is a
recently recognized member of the PLA2 family that has
been proposed to participate in signaling, membrane
remodeling, exocytosis, cell proliferation, apoptosis,
and other events, and isoforms expressed in some cells
are generated by proteolytic processing [3–10]. We have
prepared recombinant constructs of iPLA2 that contain
an N-terminal polyhistidine sequence (His-tag) or a
C-terminal His-tag that will interact with immobilized
metal affinity matrices, and these constracts have been
expressed from their cDNAs in an Sf9 insect cell-
baculovirus system.
The two constructs appeared to yield markedly
different amounts of protein in this system after prod-
nts from immunoprecipitates of C-terminal six
ifies the peak that corresponds to the truncated
no acid 46F as the N-terminus.
six myc-tagged C-terminal cleavage fragment
d mass Observed mass Charge state Similarity score
4916 424.2458 2 0.34elua
identAPP
ulate
847.
725 417.575 3 0.03
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phy (Figure 4). The N-terminal half of the iPLA2
protein sequence contains seven ankyrin-like repetitive
sequence stretches, and the C-terminal portion contains
the catalytic site and some regulatory domains. We
postulated that the low yield of the N-terminal His-tag
iPLA2 from cobalt affinity columns might reflect N-
terminal processing and loss of the His-tag, which
would prevent interaction with the cobalt affinity col-
umn and cause loss of the product during purification.
To evaluate this possibility, both SDS-PAGE bands
illustrated in the rightmost lane of Figure 4 were
excised and digested with trypsin.
The digests were analyzed by MALDI/TOF/MS to
acquire the peptide mass map and by LC/MS/MS.
The first 30 N-terminal amino acids of iPLA2 are
1MQFFGRLVNT 11LSSVTNLFSN 21PFRAKEVSLA.
The N-terminal tryptic peptide of the full-length
iPLA2 isoform is
1MQFFGR6, but this peptide is
N-acetylated and generates only a singly charged ion
that does not trigger switching from survey MS mode
to MS/MS mode on the Q-TOF [24]. The second
tryptic peptide in full-length iPLA2 is
7L-R23. Pep-
tides with residue 23 as the C-terminus and residues
8 or higher as the N-terminus represent signature
Figure 8. MS/MS spectrum of the signature p
myc-tagged C-terminal cleavage products.
Table 4. The theoretical fragment masses of signature peptide 4
in Figure 8
a ions Theoretical m/z 120.08 249.1
m/z tolerance 0.00 0.0
b ions Theoretical m/z 148.08 277.1
m/z tolerance 0.10 0.0
AA Phe Glu
y ions Theoretical m/z 847.39 700.3
m/z tolerance --- 0.1
z ions Theoretical M/z 830.36 683.2m/z tolerance - 0.11peptides that reflect N-terminal proteolytic process-
ing. Analyses of the MS/MS data of the tryptic
peptide mixture from C-terminal His-tag iPLA2 by
the SD program results in identification of three
different signature peptides (Table 2) that represent
different truncation variants (9N-P752, 12S-P752, and
13S-P752). Figure 5 illustrates the MS/MS spectra of
the corresponding signature peptides (9N-R23, 12S-
R23, and 13S-R23) and that of the tryptic peptide 7L-R23
of full-length iPLA2. The high correspondence be-
tween the fragment ions in each spectrum and the
predicted amino acid sequence demonstrates accu-
rate identification of these signature peptides. All
three signature peptides are also observed in the
MALDI/TOF mass spectrum of the tryptic digest of
C-terminal His-tagged iPLA2 (Figure 6a). The signa-
ture peptide 12SSVTNLFSNPFR23 exhibits the most
intense signal, and the signal of the tryptic peptide
7LVNTLSSVTNLFSNPFR23 of the full-length iPLA2
is only 10% of the sum of the signals for the three
other signature peptides.
Because much of the amino acid sequence of the four
peptides is identical, the relative abundances of the
different variants is likely to be approximately reflected
by the relative signal intensities of their signature
e 46FEQMHR51 from a tryptic digest of APP six
MHR51 and the m/z tolerance of experimental fragment masses
377.18 508.22 645.28 801.38
--- 0.07 0.01 ---
405.18 536.22 673.28 829.38
0.10 0.09 --- ---
Gln Met His Arg
571.28 443.22 312.18 175.12
0.06 0.09 0.03 0.02
554.25 426.19 295.15 158.09eptid6FEQ
2
1
2
5
2
0
90.05 0.07 0.03 0.08
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rus Sf9 cell system thus appears to be (9N-P752), and
full-length iPLA2 appears to be a minor component of
the iPLA2 isoform mixture. This is consistent with
Edman sequencing of recombinant iPLA2 expressed in
Sf9 cells [3]. Figure 6b is the MALDI/TOF mass spec-
trum of the tryptic digest of N-terminal His-tag iPLA2
and illustrates that the only N-terminal peptide from
full-length iPLA2 observed in the tryptic digest is
7LVNTLSSVTNLFSNPFR23. All three of the iPLA2
N-terminal truncation variants lack the His-tag and
thus fail to interact with the cobalt affinity column,
which results in their loss during affinity purification.
Identification of Potential Cleavage Sites of the C-
Terminal Fragments from an Amyloid Precursor
Protein (APP) Construct
The SD program was also applied to the more complex
biological problem of identifying the cleavage sites of
Amyloid Precursor Protein (APP) involved in the
pathogenesis of Alzheimer’s Disease [1]. These sites are
reflected by the N-terminal residue of the six myc-
tagged C-terminal APP fragment that results from the
cleavages. This fragment is also designated either as the
the APP intracellular domain (AICD) or as the carboxy-
terminal fragment generated by  secretase cleavage
(CTF). The sequence of the six myc-tagged AICD
peptide of APP is 1LVMLKKKQYT 11SIHHGVVEVD
21AAVTPEERHL 31SKMQQNGYEN 41PTYKFFEQMH
51RFKAMEQKLI 61SEEDLNEMEQ 71KLISEEDLNE
81MEQKLISEED 91LNEMEQKLIS 101EEDLNEMEQK
111LISEEDLNEM 121ESLGDLTMEQ 131KLISEEDLNS
141RPLEPLEL, and its MW about 17 kDa.
The sequence that corresponds to the six-myc tag
is 54M-L148. This tag is added to the APP construct to
facilitate immunoprecipitation from homogenates af-
ter expression in transfected cells with antibodies
directed against the tag sequence. APP can undergo
cleavage at different sites within cells to produce
different C-terminal fragments. Because APP immu-
noprecipitates (IP) obtained with agarose beads cou-
pled to antibodies directed against its myc-tag
epitope contain many components, it is impossible to
identify the APP cleavage sites from the MALDI/TOF
mass spectrum of the IP (Figure 7). We therefore
digested the eluate from the IP beads with trypsin
Table 5. Signature peptide identified from the Glu-C digest of A
Sequence Expected mass StartAA
YENPTYKFFE 1337.605 38
MQQNGYENPTYKFFE 1895.827 33
AMEQKLISEE 1177.578 54
LKKKQYTSIHHGVVEVDAAVTPE 2549.374 4
QMHRFKAME 1177.561 48
LKKKQYTSIHHGVVEVDAAVTPE 2549.374 4and Glu-C separately. The digests were then ana-lyzed by LC/MS/MS, and the data were processed
by our SD program.
The signature peptides identified from the tryptic
digest are listed in Table 3. The peptide 46FEQMHR51
arises from a nontryptic cleavage, and the similarity
score of its MS/MS spectrum (Figure 8) is 0.34. Most
of the expected theoretical fragment ion m/z values
match spectral lines in Figure 8 within 0.1 m/z units
(Table 4). Observed high abundance ions match sev-
eral expected fragment ions in the theoretical y-series
(y1, 175.12; y2, 312.21; y3, 443.31, y4, 571.33, and y5,
700.42) and in the z-series (z2, 295.18; z3, 426.25; z4,
554.30; and z5, 683.40). Several predicted ions in the
a-series and in the b-series of fragment ions also
match intense peaks in Figure 8 (Table 4). The
MS/MS spectrum in Figure 8 thus supports accurate
identification of a nontryptic cleavage product by the
SD algorithm.
Re-examination of the MALDI/TOF mass spec-
trum of the original immunoprecipitate in Figure 7
reveals a peak at m/z 12,304.84 closely matches the
predicted m/z value (12,304.73) of the C-terminal
cleavage fragment 46F-L148, which is the expected
parent polypeptide from which the 46F-R51 fragment
arises upon digestion with trypsin. All of this infor-
mation supports the identification of a potential
C-terminal fragment of the APP construct with a
C-terminal six-myc tag that is generated by cleavage
of the 45F-F46 peptide bond, and this is a cleavage site
that has not been recognized previously.
Results from digestion of the immunoprecipitate
with the alternate protease Glu-C are summarized in
Table 5. The first listed peptide is a potential signature
peptide with a similarity score of 0.30. Its tandem mass
spectrum (Figure 9) contains high intensity peaks that
match predicted fragment ions of a candidate signature
peptide. In the signature peptide sequence
45FEQMHR51 identified in Table 3, one glutamic acid
residue is located two amino acid residues away from
the N-terminal phenylalanine residue. The N-terminal
signature peptide produced by GluC digestion would
be the dipeptide FE, which is too small to be captured
on the C18 LC column and then detected by the mass
spectrometer. That is the reason why the cleavage site
45F-F46 is not identified in analyses of the Glu-C digest.
This illustrates why we recommend digesting with
ix myc-tagged C-terminal cleavage fragment
A Calculated mass Observed mass
Charge
state
Similarity
score
1337.683 669.3414 2 0.30
1895.947 948.4734 2 0.16
1177.753 589.3766 2 0.10
2549.364 850.4546 3 0.03
1177.753 589.3766 2 0.02
2549.375 1275.188 2 0.01PP s
EndA
47
47
63
26
56more than one protease and then analyzing the MS/MS
ge pr
1791J Am Soc Mass Spectrom 2004, 15, 1780–1793 CHARACTERIZATION OF N-TERMINAL PROCESSINGdata of different digests with the SD program in order
to avoid overlooking potential signature peptides.
Limitations of the Signature Peptide Discovery
Algorithm in Its Current Form
A caveat is that occasional nonspecific cleavage at
unexpected sites by trypsin or other proteases is a
limitation of any approach that relies on the sequence
specificity of a given protease, and many searching
algorithms in proteomics do so [23, 24]. Other such
algorithms and ours can be confounded by such non-
specific cleavages. The effect is that some apparent
“signature peptides” do not truly reflect in vivo pro-
cessing but are artifacts of nonspecific cleavages. The
observed “signature peptide set” must thus be assumed
to include some false positives, and a second piece of
information consistent with the proposed site of pro-
cessing is required as confirmation.
In the case of the APP peptide 46FEQMHR51, for
example, that reflects cleavage of the 45F-F46 peptide
bond, the fact that this is not a nonspecific tryptic
cleavage is indicated by finding that the original immu-
noprecipitate that had not yet been digested with tryp-
sin contained the parent polypeptide 45F-L148 from
which the tryptic product 46FEQMHR51 was subse-
quently produced. Similarly, the fact that the peptide
12SSVTNLFSNPFR23 observed in purified iPLA2 di-
gests does not reflect nonspecific tryptic cleavage is
indicated by the fact that Edman sequencing of the
undigested preparation identifies 12S as the N-terminal
residue.
It is also important when comparing actual and
theoretical mass spectra that true matches should be
distinguished from random hits [25, 42], and some
software programs, e.g., Proteometrix Sonar (Genomics
Solutions) or Mascot (Matrix Science), use other match-
ing algorithms. In our particular application, the prob-
Figure 9. MS/MS spectrum of the signature
digest of APP six myc-tagged C-terminal cleavalem of random hits is considerably reduced by the factthat our peptide tandem mass spectra are not searched
against entire protein data bases but rather against the
sequence of a specific protein, and this greatly decreases
the family of random hit candidates that have the same
parent ion m/z value (within a specified tolerance) and
somewhat similar MS/MS spectra but different amino
acid sequences than the actual peptide from which the
experimental MS/MS spectrum was produced.
Our algorithm does consider peak intensity informa-
tion in addition to m/z value and also includes a
correction factor designed to minimize discrimination
against smaller peptides, but it still represents an en-
hanced Signal Dot Product (SDP) approach. Both Se-
quest and Sonar MS/MS also use SDP as the basic
scoring algorithm [43]. The Sonar MS/MS algorithm
includes a parameter in comparing spectra designated
the “expectation value” that is designed to enhance
discrimination between random hits and true matches,
and it is based on the probability distribution of sto-
chastic SDP scores of peptide sequences [42]. Because
our application focuses on the sequence of a single
protein rather than an entire protein database, there is
an insufficient number of stochastic scores to calculate
this distribution function.
Conclusions
In the course of studying in vivo processing of the
central nervous system proteins Group VIA Phospho-
lipase A2 (iPLA2) and Amyloid Precursor Protein
(APP), and we have developed an automated method to
identify protein isoforms that arise from proteolytic
processing. Algorithms for generating sets of theoretical
signature peptides and for calculating similarity scores
to compare actual and theoretical mass spectra in our
Signature-Discovery (SD) program have been opti-
mized, and appropriate parameters have been selected
from experiments with model protein mixtures. Using
de 38YENPTYKFFE47 from a Glu-C proteolytic
oducts.peptiour optimized parameters, four different isoforms of
1792 SONG ET AL. J Am Soc Mass Spectrom 2004, 15, 1780–1793iPLA2 produced by proteolytic processing have been
identified among products derived from expression of
iPLA2 cDNA in cells. We have also used the SD
program to identify two variants of the C-terminal
cleavage fragment of an APP construct with a C-
terminal six-myc tag that represent previously unrecog-
nized cleavage sites for APP processing. These results
with iPLA2 and APP and illustrate the utlility of our
approach in identifying protein isoforms that arise from
proteolytic processing.
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